Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences.

Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences, Inc http://edmdrx.com/ . Applications have also been submitted to the next other Concerned Member Claims in the European Union: Austria, France, Germany, Italy, Spain and Portugal. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixUsing integrated molecular pathology to control incidental pancreatic cysts: an interview with Dr Ananya Das’This MAA submission closely follows the submission of our NDA to the U.S. Food and Drug Administration the other day, and marks a significant first step toward the availability of a sustained launch treatment for DME patients in European countries,’ said Dan Myers, president and CEO of Alimera.